Eric K. Singhi, MD
@lungoncdoc
Followers
6K
Following
20K
Media
1K
Statuses
8K
Thoracic Medical Oncologist, Assistant Professor @MDAndersonNews | Patient education & young-onset lung cancer | 🫁#cancer #lcsm @LungCancerRx | Views my own
Houston, TX
Joined September 2018
Our patient-focused publication on young-onset lung cancer is now published in @JAMAOnc. To every patient told they were ‘too young’ for lung cancer, and to the families who stood beside them, this is for you 🤍. @MDAndersonNews
https://t.co/kT9ZmKOBCe
2
18
51
ToxCheck: AEs for ADCs approved in Lung Cancer & how to manage them with @sands_jacob: ✅ TDXd: HER2+ ✅ DatoDXd: EGFR+ ✅ TelisoV: C-MET Full 🗣️: ⭐️ https://t.co/qG1al4sR1b ⭐️ Also on “Oncology Brothers” podcast #OncTwitter @OncUpdates @OncoAlert #lcsm
2
10
26
Thank you to this outstanding faculty for making my role as Event Chair today so seamless!! @cancerGRACE
@jryckman3 @maraantonoff @FawziAbuRous @meerapatelmd
A heartfelt thank you to our incredible faculty for making Lung Cancer OncTalk 2025 such a meaningful and impactful experience for patients and caregivers everywhere. We are deeply grateful to Drs. Eric Singhi, Fawzi Abu Rous, Jeff Ryckman, Mara Antonoff, and Meera Patel for
0
4
20
Now live! Our first panel discussion from Lung Cancer OncTalk 2025 is here. Drs. @lungoncdoc, @jryckman3, and @FawziAbuRous dive deeper into #Radiotherapy and #BispecificAntibody therapies.
1
2
5
Important results from our BREATHE study. Unique thoracic oncology pressures: 📈 Rapidly evolving treatments, late diagnoses, high mortality & patient volume all fuel burnout. 📊 62% keep up with emerging data regularly, yet 30+% struggle to keep pace. More to come.
🗨️ What did the BREATHE study show about burnout & resilience in early-career thoracic oncologists? ⭐ Don't miss this interview with @lungoncdoc, who shares insights on the data presented at #NACLC25! ➡️ Watch now: https://t.co/ojRIQ8As1S
#lcsm #LungCancer
3
6
13
Join us tomorrow!
🫁 Lung Cancer OncTalk 2025 is coming this December! Join experts, patients, and caregivers for a virtual event focused on the latest in lung cancer care and research. 🔗 Register now: https://t.co/zF7wspoydW
#OncTalk2025 #LungCancer #CancerGRACE #PatientEducation
1
3
15
Sequencing, tough cases, and tips you’ll actually use Monday morning. Join moderator Dr. @benlevylungdoc and panelists Drs. David Carbone, @MillieDas1, @MattGubensMD, Kartik Konduri, Laura Macke, @RachelSanbornMD, and @lungoncdoc for this case-driven masterclass on Advanced
0
3
12
I love being an oncologist and I love advocating for this community, but I hate lung cancer. Losing incredible people like Angus, who poured SO MUCH strength and hope into this community, is the hardest part of this work. We miss you, my dear friend. Your impact lives on. 🤍
Mourning the loss of @anguspratt, a lung cancer 🫁 patient advocate from @LungCancer_Can, whose work continues to inspire us to aim higher and fight for better services and treatments for people with #lungcancer worldwide. Your light — and your red-beanie spirit — lives on. 🙏
4
5
38
New in @JCO_ASCO CHRYSALIS-2 Cohort C shows amivantamab + lazertinib delivers meaningful and durable activity in atypical EGFR-mutated NSCLC (G719X, L861Q, S768I). ORR 52% overall, 57% in 1L, and IMPRESSIVE mPFS up to 19.5 months with no new safety signals. A real step forward
ascopubs.org
PURPOSEFor patients with advanced non–small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor (EGFR) mutations (eg, S768I, L861Q, G719X), efficacy of current treatment...
2
25
59
LIVE from #NACLC25 | NSCLC Game Plan: Navigating HER2 with Evidence & Insight
1
1
2
What an exciting few days in Chicago! Thank you to all who attended the IASLC @ASCO #NACLC2025! From early detection and biomarker research to surgical, radiation, and treatment innovations, the past few days showcased meaningful progress in #lungcancer care.
0
2
21
Grateful to present an update on the phase II eNRGy trial at #NACLC25: zenocutuzumab in pts with treatment-naive, NRG1-fusion positive NSCLC. Zenocutuzumab was FDA approved December 2024 in previously treated NSCLC and pancreatic cancer but did include some treatment naive.
4
11
44
Proud mentor moment! Our team’s single-institution study on young-onset lung cancer was presented at #NACLC25. Grateful for these incredible colleagues who share a commitment to advancing care for this pt population. More to come, stay tuned! @MDAndersonNews @maraantonoff
0
2
32
@DrewMoghanaki Thank you - finally put something together. Here’s my current version. Curious if this looks ok for a patient-centered audience (topic = metastatic NSCLC). Trying to minimize text and lean heavily on visuals. #radonc @EvanThomas84 @nbn426 @gwalls89 @lungoncdoc
1
3
15
This morning we presented some results from the BREATHE study ➡️35% of respondants experienced severe burnout by MBI ➡️ close to 50% had self reported symptoms of burnout ➡️ Over 80% still had a high sense of personal accomplishment @lungoncdoc @drshieldsmd @ipreeshagul
So proud of @ASridharMD sharing results from our BREATHE study: the first to characterize burnout in early-career thoracic oncologists. 🔥 >1 in 3 early-career oncologists affected 💡 Marriage, sleep & family responsibility appear to be protective @IASLC #NACLC25
0
3
14
Join us live on X from #NACLC25 tonight at 8:30 PM CST for our lung cancer #IDEOXchange discussing the latest developments with Drs. @ChristineBestv1 @theabzlab @lungoncdoc @GavittWoodard @marinagarassino @ajuloorimd @NarjustFlorezMD @hjrossmd @dramycummings @hari_keshava
1
6
11
Robust multidisciplinary discussion of oligometastatic NSCLC at #NACLC25 with Drs. @dwightowenmd @maraantonoff @CJTsaiMDPhD and @jillfeldman4. Impressive data but key is patient selection. When does local consolidation add benefit and when does it only add risk?
2
10
38
High rates of burnout among early-career thoracic oncology faculty were just presented at #NACLC2025—this isn’t a personal failure, it’s a systemic problem. Long hours, emotional load, and constant pressure are taking a toll. @ASridharMD @AnaVManana @IASLC
2
15
37
Dear friend & colleague @maraantonoff shares her expertise on the evolving role of surgery in stage 4 disease. #NACLC25 @IASLC
1
8
20
Lively debate #NACLC25 between @BrunaPellini and @meerapatelmd about perioperative immunotherapy with @ErinGillaspie moderating. Final vote: neoadjuvant only for pCR Perioperative for everyone else. …and surgery is still the main event!!! 😷
1
9
22